Ghisallo Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Ghisallo Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-33,750	Closed	-$859K	–	120
2024 Q3	$859K	Hold	33,750	–	–	0.04%	130
2024 Q2	$855K	Sell	33,750 -33,750	-50%	-$923K	0.07%	104
2024 Q1	$2.09M	Buy	+67,500	New	+$2.3M	0.24%	91
2023 Q3	–	Sell	-205,000	Closed	-$3.53M	–	122
2023 Q2	$3.53M	Hold	205,000	–	–	0.42%	53
2023 Q1	$3.4M	Buy	+205,000	New	+$2.39M	0.82%	27

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Ghisallo Capital Management's BBIO Position: Q4 2024 in Review

Ghisallo Capital Management sold out of BridgeBio Pharma (BBIO) in Q4 2024, closing a stake of 33,750 shares — an estimated $859K sold.

Ghisallo Capital Management first reported a position in BBIO in Q1 2023 and held it in 5 quarters. The position peaked at $3.53M in Q2 2023. 263 funds tracked by Wall St. Rank hold BBIO as of Q4 2024.

Ghisallo Capital Management reported no remaining BridgeBio Pharma position as of Q4 2024 after selling out during the quarter.
Ghisallo Capital Management sold 33,750 BridgeBio Pharma shares in Q4 2024, an estimated $859K.
Ghisallo Capital Management first reported a position in BridgeBio Pharma in Q1 2023 and held it in 5 quarters.
Ghisallo Capital Management's BridgeBio Pharma position peaked at $3.53M in Q2 2023.
263 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2024.

Based on Ghisallo Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.